A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab
AL Amyloidosis
DRUG: Teclistamab
Hematologic Complete Response (CR) rate, Percentage of participants achieving CR or better according to EHA/ISA guidelines, baseline up to 3 cycles of treatment (approximately 3 months)
Hematologic Overall Response Rate (ORR) rate, Percentage of participants achieving Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) or better according to EHA/ISA guidelines, Baseline up to progression of disease or death (approximately 3,5 years)
This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab